Follow Teva Pharmaceutical to never miss an important update.
Chief Executive Richard Francis sold roughly 10.6 million dollars worth of shares on Tuesday. While a sale of this size from the top leader often draws attention, it is common for executives to sell shares for personal financial planning after the stock has performed well.
The business itself remains focused on its shift toward higher-margin branded drugs. This sale does not change that strategy or the company's recent progress in hitting its profit targets early.
Teva held its first research and development day to show how it will move away from its roots in low-margin generic drugs. The company is now targeting between 6 billion and 7 billion dollars in annual revenue from innovative medicines by 2030. These are branded drugs that Teva develops itself, which typically earn far more profit per sale than the simple copies of other companies' drugs it has historically sold.
This shift is the core of the company's turnaround. By focusing on its own pipeline of treatments for the brain and respiratory system, Teva aims to replace the unpredictable income from generics with steadier, high-growth brands. Reaching this target would mean these specialty drugs become the primary engine of the business within the next four years.
Source: GlobeNewsWire
After Teva reported its November results, we updated our fair value and raised our assumptions for profit margins. We now expect the company to keep over 30% of its sales as operating profit two years earlier than we had previously modeled. We have added the risk from concentrated generic revenue and the volatility of research and development charges to what we track. We also adjusted our sales expectations for the neurology portfolio and deepened our projected decline for the US generics business.
Leerink Partners kept its outperform rating on the stock this week. Several other firms, including TD Cowen and H.C. Wainwright, also kept their buy ratings, with Wainwright setting a price target of $54. The average target across all analysts now sits at about $48. These updates follow a strong quarterly report where the company raised its outlook for its newest brands. Analysts are focused on whether these high-margin specialty drugs can continue to grow fast enough to replace the profits lost from older, generic medicines.
Source: Leerink Partners
The company signed an agreement with Samsung Bioepis to sell two biosimilars in the U.S. Biosimilars are near-identical copies of complex biological drugs that are usually very expensive. One drug will be available soon, while the second is planned for late 2027.
This deal helps the company hit its goal of growing its biosimilar business faster than originally planned. These products are harder to make than standard generic pills, which means they face less competition and can generate steadier profits over time.
Source: GlobeNewsWire
Management consistently sets a beatable bar and clears it, showing they have a firm handle on the business even as they shift away from older products.
| Expectation | |
|---|---|
| EPS | $0.70 |
| Revenue | $4.27B |
Follow Teva Pharmaceutical to get the latest and most important updates.
Follow TEVA